Jessica Chubak, PhD

Associate Investigator


Recent publications

Curriculum vitae (CV)




Research interests and experience

  • Cancer control: epidemiology; breast cancer; medication use; survivorship; secondary prevention; quality of life; automated data collection; screening
  • Health services & economics: chronic illness management; translation of preventive care research into clinical practice
  • Medication use & patient safety: pharmaceutical outcomes research; validation of pharmacy data resources

Jessica Chubak joined Group Health Research Institute (GHRI) in 2007 with a passion for epidemiology and improving health care. With expertise in epidemiologic methods, pharmaco-epidemiology, and cancer, she is working with the Institute's cancer researchers to explore new inquiries in cancer screening and survivorship.

Dr. Chubak serves as the GHRI site principal investigator for the HMO Cancer Research Network. She also participates in several projects on medication use and cancer risk and prognosis. She is especially interested in evaluating programs and translating research into practices that improve health and health care.

Awarded a Fulbright graduate student grant, Dr. Chubak pursued her master's degree in bioethics and health law in New Zealand. This unique background has helped shape her commitment to moving research innovations into daily practice, especially for cancer survivors. She is building a research program in cancer screening and survivorship focused on preventing cancer death, recurrence, and late and long-term adverse effects of cancer treatment. She aims to develop epidemiologic methods for large-scale research on cancer screening and care management for cancer survivors.

Dr. Chubak is an affiliate assistant professor in the Department of Epidemiology at the University of Washington School of Public Health and serves as co-chair of GHRI’s Scientific Policy Committee. A member of the American Society of Preventive Oncology and the Society for Epidemiologic Research, she also serves as a peer reviewer for a dozen journals, including Medical Care, the Journal of Oncology Practice, and the Journal of Clinical Epidemiology.


Recent publications

Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014 Apr;144(2):405-16. doi: 10.1007/s10549-014-2870-5. Epub 2014 Feb 21. PubMed

Carrell DS, Halgrim S, Tran DT, Buist DS, Chubak J, Chapman WW, Savova G. Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence. Am J Epidemiol. 2014 Jan 30 [Epub ahead of print]. doi: 10.1093/aje/kwt441. PubMed

Carrell DS, Halgrim S, Tran DT, Buist DS, Chubak J, Chapman WW, Savova G. Carrell et al. respond to "Observational research and the EHR." Am J Epidemiol. 2014 Jan 30 [Epub ahead of print]. PubMed

Wagner EH, Ludman EJ, Aiello Bowles EJ, Penfold R, Reid RJ, Rutter CM, Chubak J, McCorkle R. Nurse navigators in early cancer care: a randomized, controlled trial. J Clin Oncol. 2013 Nov 25. [Epub ahead of print]. PubMed

Laing SS, Bogart A, Chubak J, Fuller S, Green BB. Psychological distress after a positive fecal occult blood test result among members of an integrated healthcare delivery system. Cancer Epidemiol Biomarkers Prev. 2013 Nov 12. [Epub ahead of print]. PubMed

Chubak J, Aiello Bowles EJ, Tuzzio L, Ludman E, Rutter CM, Reid RJ, Wagner EH. Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system. J Cancer Surviv. 2013 Dec 19 [Epub ahead of print]. PubMed

Chubak J, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. Prev Med. 2013 Nov;57(5):671-8. doi: 10.1016/j.ypmed.2013.08.032. Epub 2013 Sep 9. PubMed

Hamilton JG, Birmingham WS, Tehranifar P, Irwin ML, Klein WM, Nebling L, Chubak J. Transitioning to independence and maintaining a career in the new funding climate: a report from the American Society of Preventive Oncology’s Junior Members Interest Group. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2138-42. doi: 10.1158/1055-9965.EPI-13-0807. PubMed

Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013 Oct 2;105(19):1456-62.doi:10.1093/jnci/djt211. Epub 2013 Aug 12. Review. PubMed

Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray SL, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1588-99. doi:10.1158/1055-9965.EPI-13-0454. Epub 2013 Jul 5. PubMed

To view more publications, please see Dr. Chubak's CV.